BioUK acquires certain key assets of SEHTA to strengthen support for life science SMEs across the UK

• Asset acquisition combines BioUK’s strength in biotech and therapeutics with SEHTA’s MedTech and HealthTech expertise, covering the full breadth of life science SMEs
• Enhances BioUK’s support offerings with SEHTA’s broad membership network and competencies in market access and grant-funding consultancy

Oxford and London, UK, 9 November 2026: BioUK Ltd., the not-for-profit membership organisation focused on catalysing success in UK life sciences, today announced that it has acquired certain key assets of SEHTA (Science and Engineering Health Technologies Alliance) through an asset purchase agreement.

Established thirty years ago, BioUK provides practical help and support to the life science ecosystem, with a core focus on R&D SMEs. The organisation aims to create connections, save its members time & money, and help secure investment through a portfolio of tailored events and services. The acquisition of selected assets from SEHTA aligns with BioUK’s mission and creates the opportunity to expand the organisation’s membership base as well as broadening BioUK’s support offerings in the areas of market access and non-dilutive investment support.

Formed in 2005, SEHTA represents a global network of more than 1,200 members working to drive innovation in healthcare. The organisation has built a reputation for supporting MedTech and HealthTech companies in their journey from concept to commercialisation through expert business support services. SEHTA’s close relationships with the NHS and expertise in health economics enable companies to better navigate the pathway into the service through strategic economic and market access advice, alongside grant writing support.

Neil Roberts (SEHTA’s Managing Director) and Clare Ansett (Operations Manager) will become part of BioUK’s transition team to support those SEHTA members who would benefit from transferring over to BioUK membership and in supporting the relationships with the previous SEHTA expert associate network. The SEHTA brand will be wholly absorbed and will operate under the BioUK brand.

Stuart Rose, CEO of BioUK, said: “The integration of some of SEHTA’s key assets is an important strategic move for BioUK, and we’re delighted to welcome its members to the BioUK community. Bringing those assets under the BioUK brand is an opportunity to expand beyond our biotech and therapeutics roots, widening our SME ecosystem and, through incorporating SEHTA’s expertise, allowing us to better fulfil our mission to catalyse success across the entire life science sector. We will be hosting a series of new membership onboarding events during November, providing an opportunity for the SEHTA community to meet us as a team and explore how we can support their growth journey.”

Neil Roberts, MD of SEHTA said: “For twenty years, SEHTA has helped MedTech and HealthTech SMEs successfully navigate the path from concept to commercialisation, and I’m proud of the community we’ve built. This asset transfer to BioUK is a real step forward for our members. They gain access to a broader nationwide network, industry leading events, more investor connections, and significant savings through BioUK’s purchasing consortium, while the market access and grant-funding expertise they value carries on. Our MedTech and HealthTech knowledge will now be included to make BioUK the prominent membership organisation within the life science sector. We look forward to supporting our members through the transition and helping them make the most of the wider benefits BioUK offers.”

To find out more about BioUK and its mission to catalyse success in life sciences, please visit: biouk.com.